Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

Ono Phar­ma­ceu­ti­cal is spend­ing $280 mil­lion up­front to take the glob­al rights of Io­n­is Phar­ma­ceu­ti­cals’ as­set for a rare blood dis­or­der, mark­ing the lat­est part­ner­ship …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER